Trastuzumab deruxtecan

Unassigned

New Medicines

Metastatic breast cancer, HER2-positive

Information

New molecular entity
Daiichi Sankyo
Daiichi Sankyo

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Antibody-drug conjugate composed of an anti-HER2 antibody, trastuzumab, and a DNA topoisomerase I inhibitor, a DX 8951 derivative. The HER2 antibody is attached to the topoisomerase I inhibitor by a tetrapeptide linker.
In 2014, there were approximately 46,500 new diagnoses of breast cancer in England. It is estimated that approximately 15-25% of women with breast cancer will have HER2-positive tumours [1].
Metastatic breast cancer, HER2-positive
Intravenous infusion